Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson’s disease

References

• Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901–5.
   PubMed Web of Science ®Google Scholar
• Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.
   PubMed Web of Science ®Google Scholar
• Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006;116(7):1744–54.
   PubMed Web of Science ®Google Scholar
• German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinsons-disease – computer visualization. Ann Neurol. 1989;26(4):507–14.
   PubMed Web of Science ®Google Scholar
• Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J. 2007;83(980):384–8.
   PubMed Web of Science ®Google Scholar
• Koo JH, Cho JY. Treadmill Exercise attenuates alpha-synuclein levels by promoting mitochondrial function and autophagy possibly via SIRT1 in the chronic MPTP/P-induced mouse model of Parkinson’s disease. Neurotox Res. 2017. doi:https://doi.org/10.1016/j.neuroscience.2017.05.016.
   Google Scholar
• Xu YD, Cui C, Sun MF, Jia XB, Zhu YL, Chu M. Neuroprotective effects of loganin on MPTP-induced Parkinson’s disease mice: neurochemistry, glial reaction and autophagy studies. J Cell. 2017. doi:https://doi.org/10.1002/jcb.26010.
   Google Scholar
• Petroske E, Meredith GE, Callen S, Totterdell S, Lau Y-S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience. 2001;106(3):589–601.
   PubMed Web of Science ®Google Scholar
• Dauer W, Kholodilov N, Vila M, Trillat A-C, Goodchild R, Larsen KE, et al. Resistance of alpha-synuclein null mice to the Parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A. 2002;99(22):14524–9.
   PubMed Web of Science ®Google Scholar
• Xu J, Kao S-Y, Lee FJS, Song W, Jin L-W, Yankner BA. Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat Med. 2002;8(6):600–6.
   PubMed Web of Science ®Google Scholar
• Arawaka S, Machiya Y, Kato T. Heat shock proteins as suppressors of accumulation of toxic prefibrillar intermediates and misfolded proteins in neurodegenerative diseases. Curr Pharm Biotechnol. 2010;11(2):158–66.
   PubMed Web of Science ®Google Scholar
• Moors TE, Hoozemans JJM, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin M-C. Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease. Mol Neurodegener. 2017;12. doi:https://doi.org/10.1186/s13024-017-0154-3.
   Google Scholar
• Yoon YM, Lee JH, Yun SP, Han YS, Yun CW, Lee HJ. Tauroursodeoxycholic acid reduces ER stress by regulating of Akt-dependent cellular prion. Sci Rep. 2016;6(39838). doi:https://doi.org/10.1038/srep39838.
   Google Scholar
• Chen Y, Zhihong Wu, Xiang Rong. Chemical chaperones reduce ER stress and adipose tissue inflammation in high. Sci Rep. 2016;6. https://doi.org/https://doi.org/10.1038/srep27486.
   Google Scholar
• Doerflinger M, Glab J, Nedeva C, Jose I, Lin A, O’Reilly L. Chemical chaperone TUDCA prevents apoptosis and improves survival during polymicrobial sepsis in mice. Sci Rep. 2016;6. doi:https://doi.org/10.1038/srep34702.
   Google Scholar
• Uppala JK, Gani AR, Ramaiah KVA. Chemical chaperone, TUDCA unlike PBA, mitigates protein aggregation efficiently and resists ER and non-ER stress induced HepG2 cell death. Sci Rep. 2017;7. doi:https://doi.org/10.1038/s41598-017-03940-1.
   Google Scholar
• van der Harg JM, Nölle A, Zwart R, Boerema AS, van Haastert ES, Strijkstra AM. The unfolded protein response mediates reversible tau phosphorylation induced by metabolic stress. Cell Death Dis. 2014;5. doi:https://doi.org/10.1038/cddis.2014.354.
   Google Scholar
• Keene CD, Rodrigues CMP, Eich T, Linehan-Stieers C, Abt A, Kren BT, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington’s disease. Exp Neurol. 2001;171(2):351–60.
   PubMed Web of Science ®Google Scholar
• Keene CD, Rodrigues CMP, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic model of Huntington’s disease. Proc Natl Acad Sci U S A. 2002;99(16):10671–6.
   PubMed Web of Science ®Google Scholar
• Keene CD, Tkac I, Steer CJ, Gruetter R, Low WC. An. Exp Neurol. 2004;187(1):211
   Google Scholar
• Rodrigues CMP, Keene CD, Linehan-Stieers C, Ma X, Low W, Steer CJ. Tauroursodeoxycholic acid prevents apoptosis induced by the neurotoxin 3-nitropropionic acid in rat neuronal cells: evidence for a mitochondrial-dependent pathway that does not involve the permeability transition. J Hepatol. 2000;32:86.
   Web of Science ®Google Scholar
• Rodrigues CMP, Stieers CL-, Keene CD, Ma X, Kren BT, Low WC, Steer CJ. Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J Neurochem. 2000;75(6):2368–79.
   PubMed Web of Science ®Google Scholar
• Cerri S, Mus L, Blandini F. Parkinson’s disease in women and Men: what’s the difference? J Parkinsons Dis. 2019;9(3):501–15.
   PubMedGoogle Scholar
• Antzoulatos E, Jakowec MW, Petzinger GM, Wood RI. Sex differences in motor behavior in the MPTP mouse model of Parkinson’s disease. Pharmacol Biochem Behav. 2010;95(4):466–72.
   PubMed Web of Science ®Google Scholar
• Burks S, Raymick J, Robinson B, Hanig J, Sarkar S. Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson’s disease mouse model: Endothelial and microglial effects. Neurosci Lett. 2019;703:86–95.
   PubMed Web of Science ®Google Scholar
• Ferguson SA, Law CD, Sarkar S. Chronic MPTP treatment produces hyperactivity in male mice which is not alleviated by concurrent trehalose treatment. Behav Brain Res. 2015;292:68–78.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Chigurupati S, Raymick J, Mann D, Bowyer JF, Schmitt T, et al. Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson’s disease mouse model. Neurotoxicology. 2014;44:250–62.
   PubMed Web of Science ®Google Scholar
• Lau YS, Novikova L, Roels C. MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact. Neurosci Res. 2005;52(4):371–8.
   PubMed Web of Science ®Google Scholar
• Barber-Singh J, Boo Seo B, Nakamaru-Ogiso E, Lau Y-S, Matsuno-Yagi A, Yagi T. Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder. Rejuvenation Res. 2009;12(4):259–67.
   PubMed Web of Science ®Google Scholar
• Stephans SE, Yamamoto BK. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse. 1994;17(3):203–9.
   PubMed Web of Science ®Google Scholar
• Kelly KA, Miller DB, Bowyer JF, O’Callaghan JP. Chronic exposure to corticosterone enhances the neuroinflammatory and neurotoxic responses to methamphetamine. J Neurochem. 2012;122(5):995–1009.
   PubMed Web of Science ®Google Scholar
• Chigurupati S, Son TG, Hyun D-H, Lathia JD, Mughal MR, Savell J, et al. Lifelong running reduces oxidative stress and degenerative changes in the testes of mice. J Endocrinol. 2008;199(2):333–41.
   PubMed Web of Science ®Google Scholar
• Paxinos G., Franklin K.B.J. The mouse brain in sterotaxic coordinates. Compact second edition. 2nd ed. Elsevier; 2003.
   Google Scholar
• Bartels T, Choi JG, Selkoe DJ. Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477(7362):107–10.
   PubMed Web of Science ®Google Scholar
• Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol. 2001;35(1):134–46.
   PubMed Web of Science ®Google Scholar
• Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest. 1998;101(12):2790–9.
   PubMed Web of Science ®Google Scholar
• Ramalho RM, Ribeiro PS, Sola S, Castro RE, Steer CJ, Rodrigues CMP. Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J Neurochem. 2004;90(3):567–75.
   PubMed Web of Science ®Google Scholar
• Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CMP, Gama MJ. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson’s disease. Mol Neurobiol. 2012;46(2):475–86.
   PubMed Web of Science ®Google Scholar
• Suresh SN, Chavalmane AK, DJ V, Yarreiphang H, Rai S, Paul A, et al. A novel autophagy modulator 6-Bio ameliorates SNCA/alpha-synuclein toxicity. Autophagy. 2017;13(7):1221–34.
   PubMed Web of Science ®Google Scholar
• Fauvet B, Fares M-B, Samuel F, Dikiy I, Tandon A, Eliezer D, Lashuel HA. Characterization of semisynthetic and naturally Nalpha-acetylated alpha-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of alpha-synuclein. J Biol Chem. 2012;287(34):28243–62.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38(8):1285–91.
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. Glial reactions in Parkinson’s disease. Mov Disord. 2008;23(4):474–83.
   PubMed Web of Science ®Google Scholar
• Dong Y, Miao Lei, Hei Long, Lin Leilei, Ding Huiqiang. Neuroprotective effects and impact on caspase-12 expression of tauroursodeoxycholic acid after acute spinal cord injury in rats. Int J Clin Exp Pathol. 2015;8(12):15871–8.
   PubMed Web of Science ®Google Scholar
• Gronbeck KR, Rodrigues CMP, Mahmoudi J, Bershad EM, Ling G, Bachour SP, Divani AA. Application of tauroursodeoxycholic acid for treatment of neurological and non-neurological diseases: Is there a potential for Treating Traumatic brain Injury? Neurocrit Care. 2016;25(1):153–66.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol. 2000;20(2):131–47.
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41–53.
   PubMed Web of Science ®Google Scholar
• Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood-brain barrier pathology in Alzheimer’s and Parkinson’s disease: implications for drug therapy. Cell Transplant. 2007;16(3):285–99.
   PubMed Web of Science ®Google Scholar
• Yamamuro A, Kishino T, Ohshima Y, Yoshioka Y, Kimura T, Kasai A, Maeda S. Proteasome inhibitor induces apoptosis through ROS generation by NOX5. J Pharmacol Sci. 2011;115:239–43.
   Web of Science ®Google Scholar
• Yanguas-Casás N, Barreda-Manso M, Nieto-Sampedro M, Romero-Ramírez L. Tauroursodeoxycholic acid reduces glial cell activation in an animal model of acute neuroinflammation. J Neuroinflammation. 2014;11:50.
   PubMed Web of Science ®Google Scholar
• Yanguas-Casas N, Barreda-Manso MA, Pérez-Rial S, Nieto-Sampedro M, Romero-Ramírez L. TGFbeta Contributes to the anti-inflammatory effects of tauroursodeoxycholic acid on an animal model of acute neuroinflammation. Mol Neurobiol. 2016. doi:https://doi.org/10.1007/s12035-016-0142-6.
   Google Scholar
• Yanguas-Casás N, Barreda-Manso MA, Nieto-Sampedro M, Romero-Ramírez L. TUDCA: an agonist of the bile acid receptor GPBAR1/TGR5 With anti-inflammatory effects in microglial cells. J Cell Physiol. 2017;232(8):2231–45.
   PubMed Web of Science ®Google Scholar
• Lo AC, Callaerts-Vegh Z, Nunes AF, Rodrigues CMP, D’Hooge R. Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice. Neurobiol Dis. 2013;50:21–9.
   PubMed Web of Science ®Google Scholar
• Nunes AF, Amaral JD, Lo AC, Fonseca MB, Viana RJS, Callaerts-Vegh Z, et al. TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-beta deposition in APP/PS1 mice. Mol Neurobiol. 2012;45(3):440–54.
   PubMed Web of Science ®Google Scholar
• Ramalho RM, Viana RJS, Low WC, Steer CJ, Rodrigues CMP. Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer’s disease. Trends Mol Med. 2008;14(2):54–62.
   PubMed Web of Science ®Google Scholar
• Moreira S, Fonseca I, Nunes MJ, Rosa A, Lemos L, Rodrigues E, et al. Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson’s disease. Exp Neurol. 2017;295:77–87.
   PubMed Web of Science ®Google Scholar
• Soares R, Ribeiro FF, Xapelli S, Genebra T, Ribeiro MF, Sebastião AM. Tauroursodeoxycholic acid Enhances mitochondrial biogenesis, neural stem cell pool, and early neurogenesis in adult rats. Mol Neurobiol. 2017. doi:https://doi.org/10.1007/s12035-017-0592-5.
   Google Scholar
• Upagupta C, Carlisle RE, Dickhout JG. Analysis of the potency of various low molecular weight chemical chaperones to prevent protein aggregation. Biochem Biophys Res Commun. 2017;486:163–70.
   PubMed Web of Science ®Google Scholar
• Gani AR, Uppala JK, Ramaiah KVA. Tauroursodeoxycholic acid prevents stress induced aggregation of proteins in vitro and promotes PERK activation in HepG2 cells. Arch Biochem Biophys. 2015;568:8–15.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhao J, Gui W, Sun D, Dai H, Xiao L, et al. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol. 2018;175(3):469–84.
   PubMed Web of Science ®Google Scholar
• Ueki A, Otsuka M. Life style risks of Parkinson’s disease: association between decreased water intake and constipation. J Neurol. 2004;251(Suppl 7):vII18–23.
   PubMedGoogle Scholar
• Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623–32.
   PubMed Web of Science ®Google Scholar
• Strandwitz P, Kim KH, Terekhova D, Liu JK, Sharma A, Levering J, et al. GABA-modulating bacteria of the human gut microbiota. Nature Microbiology. 2019;4(3):396–403.
   PubMed Web of Science ®Google Scholar
• Bambury A, Sandhu K, Cryan JF, Dinan TG. Finding the needle in the haystack: systematic identification of psychobiotics. Br J Pharmacol. 2018;175(24):4430–8.
   PubMed Web of Science ®Google Scholar
• Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009;9(1):35–51.
   PubMed Web of Science ®Google Scholar